Role of epigenetics in cardiovascular diseases: An out and out check

Rufaida Wasim, Tarique Mahmood, Mohammed Haris Siddiqui, Aditya Singh, Asad Ahmad, Farogh Ahsan

PDF(436 KB)
PDF(436 KB)
Intelligent Pharmacy ›› 2023, Vol. 1 ›› Issue (4) : 207-211. DOI: 10.1016/j.ipha.2023.09.001
Review

Role of epigenetics in cardiovascular diseases: An out and out check

Author information +
History +

Abstract

Epigenetics is a rapidly growing field that deals with the study of heritable changes in gene expression that occur without a change in DNA sequence. DNA methylation, histone modification, and noncoding or microRNAs are the three major mechanisms of epigenetics that can best explain how genes are regulated. These processes are mediated by various enzymes such as DNA methyltransferases, histone acetyltransferases, histone deacetylases, and microRNA biogenesis enzymes. Dysregulation of these enzymes can lead to various pathological conditions, including cardiovascular diseases (CVDs). In recent years, the role of epigenetics in CVDs has gained significant attention as an important regulatory key player in the pathophysiology and therapeutics of these diseases. Epigenetics is an area of scientific study that has been instrumental in exploring the mechanisms that control gene expression. It has been observed that changes in chromatin or its packaging have a large impact on DNA accessibility, which leads to modifications in various cellular processes. DNA methylation, histone modification, and noncoding or microRNAs are the primary tools used by epigenetics to regulate these changes. A variety of enzymes responsible for DNA methylation, histone modification, and microRNAs have been found to play a critical role in the onset of various CVDs (cardiovascular diseases). Epigenetics is now regarded as an important player in the regulation of cardiovascular disease at various levels, from pathophysiology to therapeutic interventions. This article comprehensively investigates the diverse epigenetic aspects which are associated with the occurrence of cardiovascular disorders.

Keywords

Cardiovascular diseases / Epigenetics / Heart failure / Histone modification

Cite this article

Download citation ▾
Rufaida Wasim, Tarique Mahmood, Mohammed Haris Siddiqui, Aditya Singh, Asad Ahmad, Farogh Ahsan. Role of epigenetics in cardiovascular diseases: An out and out check. Intelligent Pharmacy, 2023, 1(4): 207‒211 https://doi.org/10.1016/j.ipha.2023.09.001

References

[1]
Wasim R , Ansari TM , Ahsan F , et al. Pleiotropic benefits of statins in cardiovascular diseases. Drug Research. 2022 Jul 22,72(9):477-486.
[2]
The Lancet . Cardiovascular health for all. Lancet. 2013; 382: 572.
[3]
Nabel EG , Braunwald E . A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012 Jan 5;366(1):54–63.
[4]
Polonsky KS . The past 200 years in diabetes. N Engl J Med. 2012 Oct 4;367(14): 1332–1340.
[5]
Khalil CA , Roussel R , Mohammedi K , Danchin N , Marre M . Cause-specific mortality in diabetes: recent changes in trend mortality. Euro. J. Prevent. Cardiol. 2012 Jun 1; 19(3):374–381.
[6]
Feinberg AP . Epigenomics reveals a functional genome anatomy and a new approach to common disease. Nat Biotechnol. 2010 Oct;28(10):1049–1052.
[7]
Portela A , Esteller M . Epigenetic modifications and human disease. Nat Biotechnol. 2010 Oct;28(10):1057–1068.
[8]
Abbott A . Project set to map marks on genome. Nature. 2010 Feb 4;463(7281): 596–597.
[9]
Baccarelli A , Ghosh S . Environmental exposures, epigenetics and cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2012 Jul;15(4):323.
[10]
Tb M . DNA methylation: the nuts and bolts of repression. J Cell Physiol. 2007; 213: 384- 390.
[11]
Matouk CC , Marsden PA . Epigenetic regulation of vascular endothelial gene expression. Circ Res. 2008 Apr 25;102(8):873–887.
[12]
Jenuwein T , Allis CD . Translating the histone code. Science. 2001 Aug 10;293(5532): 1074–1080.
[13]
Cooper ME , El-Osta A . Epigenetics: mechanisms and implications for diabetic complications. Circ Res. 2010 Dec 10;107(12):1403–1413.
[14]
Keating S , El-Osta A . Transcriptional regulation by the Set7 lysine methyltransferase. Epigenetics. 2013 Apr 1;8(4):361–372.
[15]
Poller W , Dimmeler S , Heymans S , et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J. 2018 Aug 1;39(29):2704–2716.
[16]
Boon RA , Jaé N , Holdt L , Dimmeler S . Long noncoding RNAs: from clinical genetics to therapeutic targets? J Am Coll Cardiol. 2016 Mar 15;67(10):1214–1226.
[17]
Gusterson RJ , Jazrawi E , Adcock IM , Latchman DS . The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem. 2003 Feb 28; 278(9):6838–6847.
[18]
Kee HJ , Sohn IS , Nam KI , et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006 Jan 3;113(1):51–59.
[19]
Kook H , Lepore JJ , Gitler AD , et al. Cardiac hypertrophy and histone deacetylase–dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J. Clin. Investig. 2003 Sep 15;112(6):863–871.
[20]
Zhang QJ , Chen HZ , Wang L , Liu DP , Hill JA , Liu ZP . The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J. Clin. Investig. 2011 Jun 1;121(6):2447–2456.
[21]
Stein AB , Jones TA , Herron TJ , et al. Loss of H3K4 methylation destabilizes gene expression patterns and physiological functions in adult murine cardiomyocytes. J. Clin. Investig. 2011 Jul 1;121(7):2641–2650.
[22]
Barrick CJ , Roberts RB , Rojas M , et al. Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Heart Circ Physiol. 2009 Jul; 297(1):H65–H75.
[23]
Latronico MV , Condorelli G . MicroRNAs and cardiac pathology. Nat Rev Cardiol. 2009 Jun;6(6):418–429.
[24]
Movassagh M , Choy MK , Goddard M , Bennett MR , Down TA , Foo RS . Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS One. 2010 Jan 13;5(1):e8564.
[25]
Movassagh M , Choy MK , Knowles DA , et al. Distinct epigenomic features in end-stage failing human hearts. Circulation. 2011 Nov 29;124(22):2411–2422.
[26]
Nguyen AT , Xiao B , Neppl RL , et al. DOT1L regulates dystrophin expression and is critical for cardiac function. Genes & Dev. 2011 Feb 1;25(3):263–274.
[27]
Kaneda R , Takada S , Yamashita Y , et al. Genome-wide histone methylation profile for heart failure. Gene Cell. 2009 Jan;14(1):69–77.. Lancet. 2013; 382: 572.
[28]
Liu F , Levin MD , Petrenko NB , et al. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol. 2008 Dec 1;45(6):715–723.
[29]
Montgomery RL , Davis CA , Potthoff MJ , et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes & Dev. 2007 Jul 15;21(14):1790–1802.
[30]
Bokil NJ , Baisden JM , Radford DJ , Summers KM . Molecular genetics of long QT syndrome. Mol Genet Metabol. 2010 Sep 1;101(1):1–8.
[31]
Kim GH . MicroRNA regulation of cardiac conduction and arrhythmias. Transl Res. 2013 May 1;161(5):381–392.
[32]
Zhao Y , Ransom JF , Li A , et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007 Apr 20;129(2):303–317.
[33]
Zhao Y , Ransom JF , Li A , et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007 Apr 20;129(2):303–317.
[34]
Dai X , Liu S , Cheng L , et al. Epigenetic upregulation of H19 and AMPK inhibition concurrently contribute to S-adenosylhomocysteine hydrolase deficiency-promoted atherosclerotic calcification. Circ Res. 2022 May 13;130(10):1565–1582.
[35]
Ramachandran B , Stabley JN , Cheng SL , et al. A GTPase-activating protein–binding protein (G3BP1)/antiviral protein relay conveys arteriosclerotic Wnt signals in aortic smooth muscle cells. J Biol Chem. 2018 May 1;293(21):7942–7968.
[36]
de Oca AM , Madueno JA , Martinez-Moreno JM , et al. High-phosphate-induced calcification is related to SM22α promoter methylation in vascular smooth muscle cells. J Bone Miner Res. 2010 Sep;25(9):1996–2005.
[37]
Lin X , Li F , Xu F , et al. Aberration methylation of miR-34b was involved in regulating vascular calcification by targeting Notch1. Aging (Albany NY). 2019 May 5;11(10): 3182.
[38]
Lin X , Xu F , Cui RR , et al. Arterial calcification is regulated via an miR-204/DNMT3a regulatory circuit both in vitro and in female mice. Endocrinology. 2018 Aug;159(8): 2905–2916.
[39]
Roberts ML , Kotchen TA , Pan X , et al. Unique associations of DNA methylation regions with 24-hour blood pressure phenotypes in black participants. Hypertension. 2022 Apr;79(4):761–772.
[40]
Infante T , Del Viscovo L , De Rimini ML , Padula S , Caso P , Napoli C . Network medicine: a clinical approach for precision medicine and personalized therapy in coronary heart disease. J Atherosclerosis Thromb. 2020 Apr 1;27(4):279–302.
[41]
Schiano C , Benincasa G , Franzese M , et al. Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases. Pharmacol Therapeut. 2020 Jun 1;210:107514.
[42]
Westerman K , Fernández-Sanlés A , Patil P , et al. Epigenomic assessment of cardiovascular disease risk and interactions with traditional risk metrics. J Am Heart Assoc. 2020 Apr 21;9(8):e015299.
[43]
Schiano C , Benincasa G , Infante T , et al. Integrated analysis of DNA methylation profile of HLA-G gene and imaging in coronary heart disease: pilot study. PLoS One. 2020 Aug 13;15(8):e0236951.
[44]
Westerman K , Sebastiani P , Jacques P , Liu S , DeMeo D , Ordovás JM . DNA methylation modules associate with incident cardiovascular disease and cumulative risk factor exposure. Clin Epigenet. 2019 Dec;11(1):1–4.
[45]
Baccarelli AA , Byun HM . Platelet mitochondrial DNA methylation: a potential new marker of cardiovascular disease. Clin Epigenet. 2015 Dec;7(1):1–9.
[46]
Humeres C , Frangogiannis NG . Fibroblasts in the infarcted, remodeling, and failing heart. JACC (J Am Coll Cardiol): Basic to Transl. Sci. 2019 Jun;4(3):449–467.
[47]
Watson CJ , Collier P , Tea I , et al. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. Hum Mol Genet. 2014 Apr 15;23(8):2176–2188.
[48]
Parthymos I , Kostapanos MS , Liamis G , Florentin M . Early investigational and experimental therapeutics for the treatment of hypertriglyceridemia. J. Cardiovasc. Dev. Dis. 2022 Jan 25;9(2):42.
[49]
Hu YW , Zhao JY , Li SF , et al. RP5-833A20. 1/miR-382-5p/NFIA–dependent signal transduction pathway contributes to the regulation of cholesterol homeostasis and inflammatory reaction. Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):87–101.
[50]
Hu YW , Yang JY , Ma X , et al. A lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1- dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis. J Lipid Res. 2014 Apr 1;55(4):681–697.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
AI Summary AI Mindmap
PDF(436 KB)

Accesses

Citations

Detail

Sections
Recommended

/